Department of Medical Ethics, Lund University, Lund, Sweden.
Stem Cell Rev Rep. 2011 Nov;7(4):761-74. doi: 10.1007/s12015-011-9257-3.
While scientific community disagrees about similarities and differences between human embryonic stem (hES) cells and human induced pluripotent stem (hiPS) cells, some politicians embrace translational hiPS cell research as a replacement for translational hES cell research. We examine the ethical relevance of the main differences between hES and hiPS cell-based therapies and discuss whether, given the current state of knowledge, certain differences are essential. We discuss whether well-founded preferences can be made in hypothetical scenarios with varying levels of patient safety, treatment efficacy, treatment accessibility and ethical controversy.
虽然科学界对于人类胚胎干细胞（hES）和人类诱导多能干细胞（hiPS）之间的相似性和差异存在分歧，但一些政治家将 hiPS 细胞的转化研究作为转化 hES 细胞研究的替代品。我们研究了 hES 和 hiPS 细胞治疗之间的主要差异的伦理相关性，并讨论了在当前知识状态下，某些差异是否是必要的。我们讨论了在患者安全性、治疗效果、治疗可及性和伦理争议程度不同的假设情况下，是否可以做出有充分依据的偏好。
